Archives for November 14, 2007

Umbilical Cord Transplantation Effective Treatment

Following umbilical cord blood transplantation after a reduced intensity treatment regimen, adults with hematological diseases have a three year survival rate of almost 50% according to researchers from the University of Minnesota. The journal Blood1 has published the details of the study in their October 15th, 2007, issue.

For adult and pediatric patients with hematologic diseases who do not have a suitable related or unrelated stem cell donor, umbilical cord blood transplants have become and integral part of the management. In patients with hematological malignancies, treatment outcomes from unrelated and related donors are comparable to those patients receiving umbilical cord blood transplants according to increasing research evidence. Since many patients with malignancy worsen or die before an unrelated donor is found, a major and decided advantage of cord blood transplantation is that stem cells are available without delay.

Because of the increased nucleated cell dose, when two separate cord blood collections are infused together, adult patients have better outcome according to scientists at the University of Minnesota. On the basis of being a partial rather than a full HLA match, one of the two cord blood collections is selected. Ultimately, graft versus graft reaction would reject stem cells from the mismatched umbilical cord blood collection, but the theory is that they will contribute to initial engraftment none the less.

110 patients with high-risk or advanced hematological disease were enrolled in the study. Eligibility requirements for the study included a minimum age of 45, or significant co-morbidities that precluded the administration of a myeloablative transplant regimen. The regimen used included a single low-dose of total body irradiation, cyclophosphamide, and fludarabine. Mycophenolate mofetil and cyclosporine was used for post-transplant immunosuppression. In order to achieve the protocol prescribed dose of nucleated cells, the majority of patients (85%) required two cord bloods.

Aplastic anemia, non-Hodgkin’s lymphoma, acute and chronic leukemias, myelodysplastic syndrome, Hodgkin

Fall Seminar 2015 – Dallas-Fort Worth

Adult Stem Cell Therapy for Orthopedics and Human Diseases
Saturday, October 10th from 1:00 pm – 3:00 pm

Hilton Dallas/Southlake Town Square
1400 Plaza Place
Southlake, Texas 76092

Dr. Riordan and Dr. McKenna 300x250

Join us for informational presentions by:

Neil Riordan, PA, PhD – Founder, Riordan-McKenna Institute / Stem Cell Institute

Why Stem Cells Work: Clinical Trials for Spinal Cord Injury, Autism, Multiple Sclerosis, Rheumatoid Arthritis, and Duchenne Muscular Dystrophy

Wade McKenna, DO – Founder, Riordan-McKenna Institute

Potential of Stem Cells to Enhance Surgical and Non-Surgical Outcomes in Sports Injuries and Orthopedic Procedures

Roger Nocera, MD – Author, Cells That Heal Us From Cradle to Grave

Cells That Heal Us From Cradle to Grave

Our speakers will be on hand afterwards for a meet and greet. Light snacks will be served.

Admission is free but space is limited. All attendees must register.

Eventbrite - Riordan-McKenna Institute Stem Cell Seminar

For more information contact:

Dusty Taylor
Riordan-McKenna Institute
+1 (817) 776-8155


Powered by WordPress Popup